medigraphic.com
ISSN 1684-1824 (Electronic)

2022, Number 2

<< Back Next >>

Rev Méd Electrón 2022; 44 (2)

Skin epidermoid carcinoma treated with HeberFERON®

Fernández-Martori M, Soler-Cárdenas SF, Amador-García Y, Bello-Rivero I, Durán-Marrero K

Language: Spanish
References: 25
Page: 357-374
PDF size: 1000.79 Kb.


ABSTRACT

Introduction: there are few reports in the literature on the use of interferon in the treatment of the squamous cell carcinoma. In a primary care unit in Colon, Matanzas, HeberFERON® was implemented in this type of tumor with favorable experiences.
Objective: to describe the effectiveness of HeberFERON® in epidermoid carcinoma.
Materials and methods: an observational, descriptive study was conducted in 33 epidermoid carcinoma lesions in 29 patients. The doses were 7.0 and 10.5 MUI of antiviral activity, perilesionally infiltrated three times a week for three weeks. Clinical follow-up of patients was performed before the treatment and at 16 weeks from the beginning of the treatment. The variables were: age, sex, skin phototype, origin; location, clinical type, stage and clinical response to treatment. Four categories of response were considered: complete, partial, stable and progressive disease. The objective response (complete plus partial) was included. Data were collected in a clinical record. The Microsoft Excel and SPSS programs were used for statistical processing.
Results: 65.5 % of patients were male. 58.6 % are phototype II and of urban origin. Ages ranging from 61 to 80 years (55.2 %) predominated. There was objective response in 57.6 % (five complete and 14 partials). The superficial keratotic squamous cell carcinoma and the nodular ulcerative one showed the best responses.
Conclusions: interferon mixing was effective in all clinical subtypes of epidermoid carcinoma, although the authors suggest a second cycle of HeberFERON® or to associate it with chemotherapy when the response is not complete.


REFERENCES

  1. Camacho FM. Carcinoma espinocelular. Queratoacantomas. Carcinomas cutáneo-mucosos [Internet]. En: Conejo-Mir J, Moreno JC, Camacho FM. Tratado de Dermatología. Barcelona: Editorial Océano; 2013 [citado 01/06/2021]. p. 1183-91. Disponible en: Disponible en: https://dialnet.unirioja.es/servlet/libro?codigo=762726 1.

  2. Ministerio de Salud Pública. Dirección Nacional de Estadísticas. Anuario Estadístico de Salud 2019 [Internet]. La Habana: MINSAP; 2020 [citado 01/06/2021]. Disponible en: Disponible en: https://files.sld.cu/bvscuba/files/2020/05/Anuario-Electr%c3%b3nico-Espa%c3%b1ol-2019-ed-2020.pdf 2.

  3. Anasagasti A, García-Vega Y, Barcelona-Pérez S, et al. Tratamiento de carcinomas basocelulares y espinocelulares avanzados, recurrentes y resistentes a tratamientos previos con una formulación de IFNs con propiedades sinérgicas. Estudio prospectivo y abierto. BMC Cancer [Internet]. 2009 [citado 01/06/2021];9:262. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2724551/ 3.

  4. Fernández-Martori M, Bello-Rivero I, Duncan-Roberts Y. Treatment of Basal Cell Carcinoma with Interferons Alpha-2b and Gamma in Primary Care. MEDICC Rev. 2018;20(1). Citado en Pubmed; PMID: 34229416. [ Links ]

  5. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer. 2009;45(2):228-47. Citado en PubMed; PMID: 19097774. [ Links ]

  6. Asociación Médica Mundial. Declaración de Helsinki de la AMM - Principios éticos para las investigaciones médicas en seres humanos. 64ª Asamblea General, Fortaleza, Brasil [Internet]. Ferney-Voltaire, Francia: Asociación Médica Mundial; 2013 [citado 23/01/2021]. Disponible en: Disponible en: https://www.wma.net/es/policies-post/declaracion-de-helsinki-de-la-amm-principios-eticos-para-las-investigaciones-medicas-en-seres-humanos/ 6.

  7. Alam M, Armstrong A, Baum C, et al. Guidelines of care for the management of cutaneous squamous cell carcinoma. J Am Acad Dermatol [Internet]. 2019 [citado 23/04/2020];78(3):560-78. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6652228/ 7.

  8. Cañueto J, Román Curto C. Pronóstico y tratamiento del carcinoma epidermoide cutáneo. Piel [Internet]. 2017 [citado 01/06/2021];33(2). Disponible en: Disponible en: https://www.elsevier.es/es-revista-piel-formacion-continuada-dermatologia-21-articulo-pronostico-tratamiento-del-carcinoma-epidermoide-S021392511730062X 8.

  9. Kricker A, Armstrong B, Hansen V, et al. Basal cell carcinoma and squamous cell carcinoma growth rates and determinants of size in community patients. J Am Acad Dermatol [Internet]. 2014 [citado 01/06/2021];70:456-64. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/24373780/ 9.

  10. Fernández-Martori M. Morbilidad por tumores malignos de piel por diagnóstico histopatológico. Colón, Matanzas. 2010-2015. Rev Méd Electrón [Internet]. 2018 [citado 01/06/2021];40(4). Disponible en: Disponible en: http://revmedicaelectronica.sld.cu/index.php/rme/article/view/2152 10.

  11. W JK, Yun BM, Shin MS, et al. Effectiveness of radiotherapy for head and neck skin cancers: a single-institution study. Radiat Oncol J. 2019;37(4):293-301. Citado en PubMed; PMID: 31918468. [ Links ]

  12. González JL, Reddy ND, Cunningham K, et al. Múltiple Cutaneous Squamous Cell Carcinoma in Immunosuppressed vs Immunocompetent Patients. JAMA Dermatol [Internet]. 2019[ citado 01/06/2021];(5):625-7. Disponible en: Disponible en: https://jamanetwork.com/journals/jamadermatology/fullarticle/2728094/ 12.

  13. Ongaratto-Barazzetti D, Ongaratto-Barazzetti PH, Thomé-Cavalheiro B, et al. Quality of life and clinical and demographic characteristics of patients with cutaneous squamous cell carcinoma submitted to tumor resection by double-bladed scalpel. An Bras Dermatol [Internet]. 2019 [citado 01/06/2021];94(3):304-12. Disponible en: Disponible en: http://dx.doi.org/10.1590/abd1806-4841.20197842/ 13.

  14. Firnhaber JM. Diagnosis and Treatment of Basal Cell and Squamous Cell Carcinoma. American Family Physician. 2012;86(2). Citado en PubMed; PMID: 22962928. [ Links ]

  15. Vega Nava CT, Vega González LG, Sereno Gómez B. Carcinoma Epidermoide tratado con Metotrexato intralesional: A propósito de un caso. Actas dermosifilográficas [Internet]. 2011 [citado 01/06/2021];102(8):605-15. Disponible en: Disponible en: https://www.actasdermo.org/es-ensayo-clinico-infiltracion-intralesional-con-articulo-S0001731011001748 15.

  16. Villanueva Ramos TI, Alcalá Pérez D, Medina Bojórquez A, et al. Queratoacantoma: ¿pseudocáncer o carcinoma epidermoide? Dermatol Rev Mex [Internet]. 2012 [citado 01/06/2021];56:26-9. Disponible en: Disponible en: https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=33346 16.

  17. Brierley JD, Gospodarowicz MK, Wittekind C (eds.). TNM Classification of Malignant Tumours [Internet]. 8th17. ed. New Jersey: John Wiley & Sons; 2016 [citado 01/06/2021]. Disponible en: Disponible en: https://www.wiley.com/enad/TNM+Classification+of+Malignant+Tumours%2C+8th+Edition-p-9781119263579 17.

  18. Nazco Torres J, Labrador Díaz JF, Castro Crespo D, et al. Tratamiento de tumores de piel con SENSUS SRT-100TM en Centro Oncológico pinareño. Rev Cienc Méd [Internet]. 2019 [citado 01/06/2021];23(6):817-26. Disponible en: Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-31942019000600817 18.

  19. Iribarren O, Ramírez M, Madariaga JA, et al. Carcinoma de células escamosas de piel. Serie de casos. Rev Chil Cir [Internet]. 2018 [citado 01/06/2021];70(4):315-21. Disponible en: Disponible en: https://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0718-40262018000400315 19.

  20. Gutzmer R, Wiegand S, Kölbl O, et al. Actinic Keratosis and Cutaneous Squamous Cell Carcinoma Treatment Options. Dtsch Arztebl Int. 2019;116(37):616-26. Citado en PubMed; PMID: 32048593. [ Links ]

  21. Lengyel LZS, Gyulai GYR. Possible immunotherapies of skin cancers. Magy Onkol [Internet]. 2019 [citado 01/06/2021];63(3):239-45. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/31538441 21.

  22. Venkateswaran N, Mercado C, Galor A, et al. Comparison of topical 5-fluorouracil and interferon alfa-2b as primary treatment modalities for ocular surface squamous neoplasia. Am J Ophthalmol [Internet]. 2019 [citado 01/06/2021];199:216-22. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382615/pdf/nihms-1513224.pdf/ 22.

  23. Nava Castañeda A, Hernández Orgaz J, Garnica Hayashi L, et al. Management of Ocular Surface Squamous Neoplasia with Topical and Intralesional Interferon Alpha 2B in Mexicans. Nepal J Ophthalmol [Internet]. 2018 [citado 01/06/2021];10(20):143-50. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/31056557/ 23.

  24. Kiss N, Avci P, Bánvölgyi A, et al. Intralesional therapy for the treatment of keratoacanthoma. Dermatol Ther [Internet]. 2019 [citado 01/06/2021];32(3). Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/30866135/ 24.

  25. Ballester Caballero Y, Rodríguez Rojas JL, Campollo Rodríguez I, et al. Tratamiento con interferón alfa-2B recombinante en el carcinoma basocelular. Camagüey. 2012-2013. Rev Electrón PortalesMedicos.com [Internet]. 2015 [citado 23/04/2021];10(22):944. Disponible en: Disponible en: http://www.portalesmedicos.com/revista/vol10_n22.htm 25.




2020     |     www.medigraphic.com